(13) found decreasing circulating levels of IL-8 during treatment with ICI (2–4 weeks post-treatment) to be associated with favorable treatment response and longer overall survival in patients with melanoma and NSCLC. The gene discussed is CXCL8; the disease is non-small cell lung carcinoma.